The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Montelukast, a Leukotriene Receptor Antagonist, for the Treatment of Persistent Asthma in Children Aged 2 to 5 Years
Abstract
Background.: The greatest prevalence of asthma is in preschool children; however, the clinical utility of asthma therapy for this age group is limited by a narrow therapeutic index, long-term tolerability, and frequency and/or difficulty of administration. Inhaled corticosteroids and inhaled cromolyn are the most commonly prescribed controller therapies for young children with persistent asthma, although very young patients may have difficulty using inhalers, and dose delivery can be variable. Moreover, reduced compliance with inhaled therapy relative to orally administered therapy has been reported. One potential advantage of montelukast is the ease of administering a once-daily chewable tablet; additionally, no tachyphylaxis or change in the safety profile has been evidenced after up to 140 and 80 weeks of montelukast therapy in adults and pediatric patients aged 6 to 14 years, respectively. To our knowledge, this represents the first large, multicenter study to address the effects of a leukotriene receptor antagonist in children younger than 5 years of age with persistent asthma, as well as one of the few asthma studies that incorporated end points validated for use in preschool children. Objective.: Our primary objective was to determine the safety profile of montelukast, an oral leukotriene receptor antagonist, in preschool children with persistent asthma. Secondarily, the effect of montelukast on exploratory measures of asthma control was also studied. Design and Statistical Analysis.: We conducted a double-blind, multicenter, multinational study at 93 centers worldwide: including 56 in the United States, and 21 in countries in Africa, Australia, Europe, North America, and South America. In this study, we randomly assigned 689 patients (aged 2–5 years) to 12 weeks of treatment with placebo (228 patients) or 4 mg of montelukast as a chewable tablet (461 patients) after a 2-week placebo baseline period. Patients had a history of physician-diagnosed asthma requiring use of β-agonist and a predefined level of daytime asthma symptoms. Caregivers answered questions twice daily on a validated, asthma-specific diary card and, at specified times during the study, completed a validated asthma-specific quality-of-life questionnaire. Physicians and caregivers completed a global evaluation of asthma control at the end of the study. Efficacy end points included: daytime and overnight asthma symptoms, daily use of β-agonist, days without asthma, frequency of asthma attacks, number of patients discontinued because of asthma, need for rescue medication, physician and caregiver global evaluations of change, asthma-specific caregiver quality of life, and peripheral blood eosinophil counts. Although exploratory, the efficacy end points were predefined and their analyses were written in a data analysis plan before study unblinding. At screening and at study completion, a complete physical examination was performed. Routine laboratory tests were drawn at screening and weeks 6 and 12, and submitted to a central laboratory for analysis. Adverse effects were collected from caregivers at each clinic visit. An intention-to-treat approach, including all patients with a baseline measurement and at least 1 postrandomization measurement, was performed for all efficacy end points. An analysis-of-variance model with terms for treatment, study center and stratum (inhaled/nebulized corticosteroid use, cromolyn use, or none) was used to estimate treatment group means and between-group differences and to construct 95% confidence intervals. Treatment-by-age, -sex, -race, -radioallergosorbent test, -stratum, and -study center interactions were evaluated by including each term separately. Fisher's exact test was used for between-group comparisons of the frequency of asthma attacks, discontinuations from the study because of worsening asthma, need for rescue medication, and the frequencies of adverse effects. Because of an imbalance in baseline values for eosinophil counts for the 2 treatment groups, an analysis of covariance was performed on the eosinophil change from baseline with the patient's baseline as covariate. Study Participants.: Of the 689 patients enrolled, approximately 60% were boys and 60% were white. Patients were relatively evenly divided by age: 21%, 24%, 30%, and 23% were aged 2, 3, 4, and 5 years, respectively. For 77% of the patients, asthma symptoms first developed during the first 3 years of life. During the placebo baseline period, patients had asthma symptoms on 6.1 days/week and used β-agonist on 6.0 days/week. Results.: In over 12 weeks of treatment of patients aged 2 to 5 years, montelukast administered as a 4-mg chewable tablet produced significant improvements compared with placebo in multiple parameters of asthma control including: daytime asthma symptoms (cough, wheeze, trouble breathing, and activity limitation); overnight asthma symptoms (cough); the percentage of days with asthma symptoms; the percentage of days without asthma; the need for β-agonist or oral corticosteroids; physician global evaluations; and peripheral blood eosinophils. The clinical benefit of montelukast was evident within 1 day of starting therapy. Improvements in asthma control were consistent across age, sex, race, and study center, and whether or not patients had a positive radioallergosorbent test. Montelukast demonstrated a consistent effect regardless of concomitant use of inhaled/nebulized corticosteroid or cromolyn therapy. Caregiver global evaluations, the percentage of patients experiencing asthma attacks, and improvements in quality-of-life scores favored montelukast, but were not significantly different from placebo. There were no clinically meaningful differences between treatment groups in overall frequency of adverse effects or of individual adverse effects, with the exception of asthma, which occurred significantly more frequently in the placebo group. There were no significant differences between treatment groups in the frequency of laboratory adverse effects or in the frequency of elevated serum transaminase levels. Approximately 90% of the patients completed the study. Conclusions.: Oral montelukast (4-mg chewable tablet) administered once daily is effective therapy for asthma in children aged 2 to 5 years and is generally well tolerated without clinically important adverse effects. Similarly, in adults and children aged 6 to 14 years, montelukast improves multiple parameters of asthma control. Thus, this study confirms and extends the benefit of montelukast to younger children with persistent asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-Term Effects of Budesonide or Nedocromil in Children with Asthma
(2000) · New England Journal of Medicine · doi:10.1056/nejm200010123431501 · Cited by 1,365
Leukotrienes are potent constrictors of human bronchi
Dahlén, S.-E., Hedqvist, P., Hammarström, S., & Samuelsson, B. (1980) · Nature · doi:10.1038/288484a0 · Cited by 958
Treatment of Asthma with Drugs Modifying the Leukotriene Pathway
Drazen, J. M., Israel, E., & O'Byrne, P. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400306 · Cited by 820
Measuring quality of life in the parents of children with asthma
Juniper, E. F., Guyatt, G. H., Feeny, D. H., Ferrie, P. J., Griffith, L. E., & Townsend, M. (1996) · Quality of Life Research · doi:10.1007/bf00435966 · Cited by 624
Leff, J. A., Busse, W. W., Pearlman, D., Bronsky, E. A., Kemp, J., Hendeles, L., Dockhorn, R., Kundu, S., Zhang, J., Seidenberg, B. C., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807163390302 · Cited by 552
Self-citationLeukotriene E4 and granulocytic infiltration into asthmatic airways
Laitinen, L. A., Haahtela, T., Vilkka, V, Lee, T. H., & Spur, B. W. (1993) · The Lancet · doi:10.1016/0140-6736(93)91073-u · Cited by 526
Reiss, T. F. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.11.1213 · Cited by 484
Self-citationMontelukast for Chronic Asthma in 6- to 14-Year-Old Children: A Randomized, Double-blind Trial
Knorr, B., Matz, J., Bernstein, J. A., Nguyen, H., Seidenberg, B. C., Reiss, T. F., Becker, A., & for the Pediatric Montelukast Study Group (1998) · JAMA · doi:10.1001/jama.279.15.1181 · Cited by 478
Self-citationThe Childhood Asthma Management Program (CAMP)
(1999) · Controlled Clinical Trials · doi:10.1016/s0197-2456(98)00044-0 · Cited by 352
Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma
LAVIOLETTE, M., MALMSTROM, K., LU, S., CHERVINSKY, P., PUJET, J.-C., PESZEK, I., ZHANG, J., & REISS, T. F. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.6.9803042 · Cited by 350
Self-citation
Cited by
Allergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
British Guideline on the Management of Asthma
British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) · Thorax · doi:10.1136/thx.2008.097741 · Cited by 2,021
Beydon, N., Davis, S. D., Lombardi, E., Allen, J. L., Arets, H. G. M., Aurora, P., Bisgaard, H., Davis, G. M., Ducharme, F. M., Eigen, H., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200605-642st · Cited by 1,250
Self-citationBrand, P. L. P., Baraldi, E., Bisgaard, H., Boner, A. L., Castro-Rodriguez, J. A., Custovic, A., de Blic, J., de Jongste, J. C., Eber, E., Everard, M. L., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00002108 · Cited by 857
Self-citationDiagnosis and treatment of asthma in childhood: a PRACTALL consensus report
Bacharier, L. B., Boner, A., Carlsen, K. ‐., Eigenmann, P. A., Frischer, T., Götz, M., Helms, P. J., Hunt, J., Liu, A., Papadopoulos, N., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01586.x · Cited by 640
Montelukast Reduces Asthma Exacerbations in 2- to 5-Year-Old Children with Intermittent Asthma
Bisgaard, H., Zielen, S., Garcia-Garcia, M. L., Johnston, S. L., Gilles, L., Menten, J., Tozzi, C. A., & Polos, P. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-894oc · Cited by 360
Self-citationGlobal strategy for the diagnosis and management of asthma in children 5 years and younger
Pedersen, S. E., Hurd, S. S., Lemanske, R. F., Becker, A., Zar, H. J., Sly, P. D., Soto‐Quiroz, M., Wong, G., & Bateman, E. D. (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21321 · Cited by 326
Leukotriene Modifier Therapy for Mild Sleep-disordered Breathing in Children
Goldbart, A. D., Goldman, J. L., Veling, M. C., & Gozal, D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1064oc · Cited by 316
Chauhan, B. F., & Ducharme, F. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002314.pub3 · Cited by 306
Prevalence of asthma‐like symptoms in young children
Bisgaard, H., & Szefler, S. (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20644 · Cited by 303
Self-citationBacharier, L. B., Phillips, B. R., Zeiger, R. S., Szefler, S. J., Martinez, F. D., Lemanske, R. F., Sorkness, C. A., Bloomberg, G. R., Morgan, W. J., Paul, I. M., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.09.029 · Cited by 270
Kheirandish, L., Goldbart, A. D., & Gozal, D. (2006) · Pediatrics · doi:10.1542/peds.2005-0795 · Cited by 261
De Civita, M., Regier, D., Alamgir, A. H., Anis, A. H., FitzGerald, M. J., & Marra, C. A. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523070-00003 · Cited by 257
Non‐surgical treatment of adenoidal hypertrophy: The role of treating IgE‐mediated inflammation
Scadding, G. (2010) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2010.01012.x · Cited by 72
Metadata
- Authors
- Knorr, B., Franchi, L. M., Bisgaard, H., Vermeulen, J. H., LeSouef, P., Santanello, N., Michele, T. M., Reiss, T. F., Nguyen, H. H., & Bratton, D. L.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2001-09-01
- Volume
- 108
- Issue
- 3
- Pages
- e48-e48
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2151589341
- Cited by
- 389
- References
- 35
- FWCI
- 13.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.